Author:
Chen Yi-Chun,Hua Wei-Kai,Hsu Jeff C.,Chang Peter S.,Wen Kuo-Lan Karen,Huang Yi-Wun,Tsai Jui-Cheng,Kao Yi-Hsin,Wu Pei-Hua,Wang Po-Nan,Chen Ke-Fan,Liao Wan-Ting,Wu Sareina Chiung-Yuan
Abstract
AbstractChimeric antigen receptor T (CAR-T) cell therapy has the potential to transform cancer treatment. However, CAR-T therapy application is currently limited to certain types of relapsed/refractory B cell lymphomas. To unlock the full potential of CAR-T therapy, technologic breakthroughs will be needed in multiple areas, including optimization of autologous CAR-T development, shortening the innovation cycle, and further manufacturing advancement of next-generation CAR-T therapies. Here, we established a simple and robust virus-free multiplexQuantum CART™system that seamlessly and synergistically integrates four platforms: 1.GTailor™for rapid identification of lead CAR construct design, 2.Quantum Nufect™for effective but gentle electroporation-based gene delivery, 3.Quantum pBac™, featuring a virus-free transposon-based vector with large payload capacity and integration profile similar to retrovirus, and 4.iCellar™for robust and high-quality CAR+T memory stem cell expansion. This robust, virus-free multiplexQuantum CART™system is expected to unleash the full potential of CAR-T therapy for treating diseases.
Publisher
Cold Spring Harbor Laboratory
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献